MAAS Multicentre Anti-Atheroma

Simvastatin, pravastatin, and lovastatin have been shown to slow the progression of coronary atheromatous lesions by 2 years after starting treatment, compared with standard care (Blankenhorn et al., 1993 Multicentre Anti-Atheroma Study [MAAS] investigators, 1994 Waters et al., 1994 Jukema et al, 1995). These studies generally reported fewer new lesions and/or total occlusions in the treated group, but regression is less well established, although it may occur in some patients. All of these stud-... 

Fig. 7. Effects of simvastatin on coronary artery minimal lumen diameter in the Multicentre Anti-Atheroma Study (MAAS).

---